Nazem Atassi1, James Berry2, Amy Shui2, Neta Zach2, Alexander Sherman2, Ervin Sinani2, Jason Walker2, Igor Katsovskiy2, David Schoenfeld2, Merit Cudkowicz2, Melanie Leitner2. 1. From the Neurological Clinical Research Institute (NCRI), Department of Neurology (N.A., J.B., A. Sherman, E.S., J.W., I.K., M.C.), and the Biostatistics Center (A. Shui, D.S.), Massachusetts General Hospital, Boston; and Prize4Life (N.Z., M.L.), Cambridge, MA. natassi@partners.org. 2. From the Neurological Clinical Research Institute (NCRI), Department of Neurology (N.A., J.B., A. Sherman, E.S., J.W., I.K., M.C.), and the Biostatistics Center (A. Shui, D.S.), Massachusetts General Hospital, Boston; and Prize4Life (N.Z., M.L.), Cambridge, MA.
Abstract
OBJECTIVE: To pool data from completed amyotrophic lateral sclerosis (ALS) clinical trials and create an open-access resource that enables greater understanding of the phenotype and biology of ALS. METHODS: Clinical trials data were pooled from 16 completed phase II/III ALS clinical trials and one observational study. Over 8 million de-identified longitudinally collected data points from over 8,600 individuals with ALS were standardized across trials and merged to create the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. This database includes demographics, family histories, and longitudinal clinical and laboratory data. Mixed effects models were used to describe the rate of disease progression measured by the Revised ALS Functional Rating Scale (ALSFRS-R) and vital capacity (VC). Cox regression models were used to describe survival data. Implementing Bonferroni correction, the critical p value for 15 different tests was p = 0.003. RESULTS: The ALSFRS-R rate of decline was 1.02 (±2.3) points per month and the VC rate of decline was 2.24% of predicted (±6.9) per month. Higher levels of uric acid at trial entry were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.02). Higher levels of creatinine at baseline were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.01). Finally, higher body mass index (BMI) at baseline was associated with longer survival (p < 0.0001). CONCLUSION: The PRO-ACT database is the largest publicly available repository of merged ALS clinical trials data. We report that baseline levels of creatinine and uric acid, as well as baseline BMI, are strong predictors of disease progression and survival.
OBJECTIVE: To pool data from completed amyotrophic lateral sclerosis (ALS) clinical trials and create an open-access resource that enables greater understanding of the phenotype and biology of ALS. METHODS: Clinical trials data were pooled from 16 completed phase II/III ALS clinical trials and one observational study. Over 8 million de-identified longitudinally collected data points from over 8,600 individuals with ALS were standardized across trials and merged to create the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. This database includes demographics, family histories, and longitudinal clinical and laboratory data. Mixed effects models were used to describe the rate of disease progression measured by the Revised ALS Functional Rating Scale (ALSFRS-R) and vital capacity (VC). Cox regression models were used to describe survival data. Implementing Bonferroni correction, the critical p value for 15 different tests was p = 0.003. RESULTS: The ALSFRS-R rate of decline was 1.02 (±2.3) points per month and the VC rate of decline was 2.24% of predicted (±6.9) per month. Higher levels of uric acid at trial entry were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.02). Higher levels of creatinine at baseline were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.01). Finally, higher body mass index (BMI) at baseline was associated with longer survival (p < 0.0001). CONCLUSION: The PRO-ACT database is the largest publicly available repository of merged ALS clinical trials data. We report that baseline levels of creatinine and uric acid, as well as baseline BMI, are strong predictors of disease progression and survival.
Authors: R G Miller; F A Anderson; W G Bradley; B R Brooks; H Mitsumoto; T L Munsat; S P Ringel Journal: Neurology Date: 2000-01-11 Impact factor: 9.910
Authors: M E Cudkowicz; J M Shefner; D A Schoenfeld; R H Brown; H Johnson; M Qureshi; M Jacobs; J D Rothstein; S H Appel; R M Pascuzzi; T D Heiman-Patterson; P D Donofrio; W S David; J A Russell; R Tandan; E P Pioro; K J Felice; J Rosenfeld; R N Mandler; G M Sachs; W G Bradley; E M Raynor; G D Baquis; J M Belsh; S Novella; J Goldstein; J Hulihan Journal: Neurology Date: 2003-08-26 Impact factor: 9.910
Authors: Vincent Meininger; Gilbert Bensimon; Walter R Bradley; Benjamin Brooks; Patrice Douillet; Andrew A Eisen; Lucette Lacomblez; P Nigel Leigh; Wim Robberecht Journal: Amyotroph Lateral Scler Other Motor Neuron Disord Date: 2004-06
Authors: Mary K Floeter; Bryan J Traynor; Jennifer Farren; Laura E Braun; Michael Tierney; Edythe A Wiggs; Tianxia Wu Journal: Neurology Date: 2017-06-14 Impact factor: 9.910
Authors: Jonathan D Glass; Vicki S Hertzberg; Nicholas M Boulis; Jonathan Riley; Thais Federici; Meraida Polak; Jane Bordeau; Christina Fournier; Karl Johe; Tom Hazel; Merit Cudkowicz; Nazem Atassi; Lawrence F Borges; Seward B Rutkove; Jayna Duell; Parag G Patil; Stephen A Goutman; Eva L Feldman Journal: Neurology Date: 2016-06-29 Impact factor: 9.910
Authors: Jinsy A Andrews; Lisa Meng; Sarah F Kulke; Stacy A Rudnicki; Andrew A Wolff; Michael E Bozik; Fady I Malik; Jeremy M Shefner Journal: JAMA Neurol Date: 2018-01-01 Impact factor: 18.302
Authors: Ming Tang; Chao Gao; Stephen A Goutman; Alexandr Kalinin; Bhramar Mukherjee; Yuanfang Guan; Ivo D Dinov Journal: Neuroinformatics Date: 2019-07
Authors: Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn Journal: Muscle Nerve Date: 2015-12-29 Impact factor: 3.217